05-JUL-2022 6:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

THERAPEUTIC STUDIES ONLY (TXCA=Y)

51% of Calendar Year is Past

COMMITTEE Base Accrual
2010		 2022
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2022
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
BREAST 1558 59 4% 115 -1442 161 -1397
ERLYTX 76 7 9% 13 -62 30 -46
GI 476 49 10% 96 -379 113 -363
GU 450 189 42% 370 -79 409 -41
GYN 57 0 0% 0 -57 0 -57
LEUK 150 46 31% 90 -59 108 -42
LUNG 524 179 34% 351 -172 338 -186
LYMPH 172 272 158% 533 361 510 338
MELAN 55 58 105% 113 58 128 73
MMYEL 147 165 112% 323 176 344 197
OTHER 0 25   49 49 47 47
  0 2   3 3 3 3
SXQOL 0 0   0 0 5 5
Total 3665 1051   2056 -1603 2196 -1469

05-JUL-2022 6:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

NON-THERAPEUTIC STUDIES ONLY (TXCA=N)

51% of Calendar Year is Past

COMMITTEE Base Accrual
2010		 2022
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2022
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
  3 6 200% 11 8 6 3
BREAST 37 1 3% 1 -35 1 -36
CCD 0 91   178 178 184 184
GU 0 11   21 21 24 24
LEUK 69 0 0% 0 -69 0 -69
LUNG 43 299 695% 586 543 508 465
LYMPH 53 0 0% 0 -53 0 -53
MMYEL 92 0 0% 0 -92 0 -92
OTHER 0 45   88 88 120 120
PEOLC 0 16   31 31 32 32
PREV 0 471   924 924 1011 1011
SURV 0 13   25 25 25 25
SXQOL 888 303 34% 594 -293 697 -191
Total 1185 1256   2459 1276 2608 1423

05-JUL-2022 6:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS

51% of Calendar Year is Past

COMMITTEE Base Accrual
2010		 2022
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2022
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
  3 6 200% 11 8 6 3
BREAST 1595 60 4% 117 -1477 162 -1433
CCD 0 91   178 178 184 184
ERLYTX 76 7 9% 13 -62 30 -46
GI 476 49 10% 96 -379 113 -363
GU 450 200 44% 392 -57 433 -17
GYN 57 0 0% 0 -57 0 -57
LEUK 219 46 21% 90 -128 108 -111
LUNG 567 478 84% 938 371 846 279
LYMPH 225 272 121% 533 308 510 285
MELAN 55 58 105% 113 58 128 73
MMYEL 239 165 69% 323 84 344 105
OTHER 0 70   137 137 167 167
  0 2   3 3 3 3
PEOLC 0 16   31 31 32 32
PREV 0 471   924 924 1011 1011
SURV 0 13   25 25 25 25
SXQOL 888 303 34% 594 -293 702 -186
Total 4850 2307   4518 -326 4804 -46

05-JUL-2022 6:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

THERAPEUTIC REGISTRATIONS BY SWOG INSTITUTIONS ONLY (TXCA=Y)

51% of Calendar Year is Past

COMMITTEE Base Accrual
2010		 2022
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2022
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
BREAST 1012 51 5% 100 -911 127 -885
ERLYTX 76 5 7% 9 -66 20 -56
GI 418 42 10% 82 -335 103 -315
GU 375 129 34% 253 -121 278 -97
GYN 57 0 0% 0 -57 0 -57
LEUK 122 38 31% 74 -47 94 -28
LUNG 441 121 27% 237 -203 240 -201
LYMPH 129 122 95% 239 110 237 108
MELAN 55 38 69% 74 19 88 33
MMYEL 85 97 114% 190 105 209 124
OTHER 0 25   49 49 47 47
  0 2   3 3 3 3
SXQOL 0 0   0 0 5 5
Total 2770 670   1310 -1454 1451 -1319

05-JUL-2022 6:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

NON-THERAPEUTIC STUDIES FOR SWOG INSTITUTIONS ONLY (TXCA=N)

51% of Calendar Year is Past

COMMITTEE Base Accrual
2010		 2022
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2022
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
  3 6 200% 11 8 6 3
BREAST 10 1 10% 1 -8 1 -9
CCD 0 84   164 164 175 175
GU 0 11   21 21 24 24
LEUK 69 0 0% 0 -69 0 -69
LUNG 30 160 533% 313 283 281 251
LYMPH 53 0 0% 0 -53 0 -53
MMYEL 92 0 0% 0 -92 0 -92
OTHER 0 45   88 88 120 120
PEOLC 0 7   13 13 19 19
PREV 0 339   665 665 764 764
SURV 0 10   19 19 22 22
SXQOL 750 237 32% 465 -284 543 -207
Total 1007 900   1760 755 1955 948

05-JUL-2022 6:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS BY SWOG INSTITUTIONS ONLY

51% of Calendar Year is Past

COMMITTEE Base Accrual
2010		 2022
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2022
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
  3 6 200% 11 8 6 3
BREAST 1022 52 5% 102 -919 128 -894
CCD 0 84   164 164 175 175
ERLYTX 76 5 7% 9 -66 20 -56
GI 418 42 10% 82 -335 103 -315
GU 375 140 37% 274 -100 302 -73
GYN 57 0 0% 0 -57 0 -57
LEUK 191 38 20% 74 -116 94 -97
LUNG 471 281 60% 551 80 521 50
LYMPH 182 122 67% 239 57 237 55
MELAN 55 38 69% 74 19 88 33
MMYEL 177 97 55% 190 13 209 32
OTHER 0 70   137 137 167 167
  0 2   3 3 3 3
PEOLC 0 7   13 13 19 19
PREV 0 339   665 665 764 764
SURV 0 10   19 19 22 22
SXQOL 750 237 32% 465 -284 548 -202
Total 3777 1570   3072 -699 3406 -371

05-JUL-2022 6:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS TO CANCER CONTROL STUDIES

51% of Calendar Year is Past

COMMITTEE Base Accrual
2010		 2022
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2022
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
BREAST 65 15 23% 29 -35 75 10
CCD 0 91   178 178 184 184
ERLYTX 0 0   0 0 1 1
GI 81 11 14% 21 -59 38 -43
GU 215 153 71% 300 85 351 136
LEUK 0 14   27 27 22 22
LUNG 53 79 149% 155 102 152 99
LYMPH 7 241 3443% 472 465 432 425
MELAN 0 0   0 0 0 0
MMYEL 0 7   13 13 11 11
OTHER 0 7   13 13 19 19
  0 0   0 0 1 1
PEOLC 0 16   31 31 32 32
PREV 0 232   455 455 486 486
SURV 0 13   25 25 25 25
SXQOL 880 303 34% 594 -285 702 -178
Total 1301 1182   2313 1015 2531 1230

05-JUL-2022 6:11

SWOG OPEN AND TEMPORARILY CLOSED STUDIES

Comm. Phase Study Stat
Center		 Open
Date		 Months
Open		 Total
Regs		 Accrual
Goal		 Monthly
Accrual
Rate		 Date of
Expected Closure or
Temporary Closure
    S2015 SWOG     6      
  BIOL SLA01 LA Gastric Ca, Immune Checkpoint Expression SWOG 02APR2019:00:00:00 39 0 400 0.0 > 15 Yrs
BREAST I-II EA1183 Brst, Met, FDG PET Assess Response, FEATURE ECOG-ACRIN 02APR2020:00:00:00   10   0.2  
  II EA1181 BRST, HER2-pCR, Preop THP and Postop HP ECOG-ACRIN 11FEB2020:00:00:00   82   6.2  
    NRGBR005 Br, Stg II&IIIA, Post NAdj Chemo Br Conserv NRG 13APR2017:00:00:00   7     Jul-2019 Temp Close
    S1706 Breast, Inflammatory, RT +/- Olaparib SWOG 12SEP2018:00:00:00 45 104 300 1.2 Jun-2036
    S2007 Breast, Brain Mets, Sacituzumab Govitecan SWOG 15DEC2020:00:00:00 18 11 44 1.2 Nov-2024
  II-III NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA NRG 24DEC2014:00:00:00   1     Sep-2019 Temp Close
  III A011202 Breast, Nodal XRT +/- ALND ALLIANCE 07FEB2014:00:00:00   129   0.0  
    A011801 BRST, HER2+, T-DM1+Placebo v T-DM1+Tucatinib ALLIANCE 06JAN2021:00:00:00   10   0.5  
    MA39 BREAST, Node-Pos, Reg RT vs No Reg RT CCTG 30MAY2018:00:00:00   10   0.3  
    NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo NRG 22JAN2015:00:00:00   89   0.0  
    NRGBR004 BREAST, Met HER2+, Pac+Tras+Pert +/- Atezo NRG 12MAR2019:00:00:00   9   0.3  
    NRGBR007 Breast, Stg I, De-Escalation of Breast RT NRG 07JUN2021:00:00:00   1   0.2  
CCD II EAQ171CD Smoke Free Support Study 2.0 ECOG-ACRIN 11APR2019:00:00:00   3   0.3  
  III A191901 Brst, Text/Motivational Intervention ET Adher ALLIANCE 10DEC2020:00:00:00   36   2.7  
    S1703 Met Breast, STM-monitoring v Usual Care SWOG 16JUL2018:00:00:00 47 228 1320 4.7 > 15 Yrs
    S1912CD CREDIT, Fin Counseling to reduce Fin Hardship SWOG 26JUL2021:00:00:00 11 30 536 4.0 Jan-2033
  OTHER A231601C CCD, OPTI-Surg in older cancer patients ALLIANCE 01APR2019:00:00:00   1   0.0  
    A231602C Blood Cancer, Assess Financial Difficulty ALLIANCE 15MAR2019:00:00:00   4     Feb-2021 Temp Close
    A231701C Brst, Srg Decision Engagement ALLIANCE 01MAR2019:00:00:00   1   0.0  
    A231901C Breast, Shared Decision Engagement System ALLIANCE 15JAN2021:00:00:00   1   0.2  
    ACCL16N1 Guideline Consistent Treatment AYA ALL COG 18DEC2017:00:00:00   54     Mar-2020 Temp Close
    NHLBIMDS LEUK, National MDS Study ECOG-ACRIN 05APR2016:00:00:00   166   3.2  
    NRGCC007 CCD, Increased Dose of SCP in Pros Survivors NRG 27MAR2019:00:00:00   23   0.2  
ERLYTX II S1609 Rare Tumor, Comb Nivo/Ipi SWOG 13JAN2017:00:00:00 65 793 818 0.7 Aug-2025
  II-III S2012 Small Cell NEC, Stg IV, Combo Chemo +/- Atezo SWOG 02DEC2021:00:00:00 7 1 189 0.2 > 15 Yrs
  III AGCT1531 Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult COG 08MAY2017:00:00:00   1   0.0  
  OTHER EAY131 MATCH ECOG-ACRIN 12AUG2015:00:00:00   183   0.0  
GI II EA2182 Anal, Erly, DECREASE ECOG-ACRIN 12NOV2019:00:00:00   2   0.3  
    EA2186 PANC, mets, Gem+Abraxane vs 5-FU+LV+Nal-IRI ECOG-ACRIN 18JUN2020:00:00:00   16   0.3  
    EA2187 ICC, Carboplatin+Paclitaxel +/- Pevonedistat ECOG-ACRIN 31JAN2020:00:00:00   7   0.0  
    S1922 Small Bowel,Ram+Pac vs FOLFIRI, mets/unresect SWOG 16DEC2019:00:00:00 30 21 94 0.3 > 15 Yrs
    S2001 Rando II, Mets Pancreas , BRCA1/2, Comb Chemo SWOG 04DEC2020:00:00:00 19 15 88 1.7 Feb-2026
    S2104 Panc,Resect High-risk,Postop Adj Chemo vs Obs SWOG 14OCT2021:11:13:50 8 4 154 0.7 > 15 Yrs
    S2107 Colorectal, BRAF mut, Enc + CET +/-Nivo SWOG 06JUN2022:10:01:28 0 0 84    
  II-III EA2174 Esoph, Peri-Op Nivolumab +/- Ipilimumab ECOG-ACRIN 17JAN2019:00:00:00   2   0.2  
    EA2197 Gal, Rando Perioperative TX ECOG-ACRIN 22DEC2020:00:00:00   2   0.2  
    NRGGI005 COLON,Stg IIA, ctDNA in Adjuvant Chemotherapy NRG 16DEC2019:00:00:00 30 20   1.2  
  III A021502 Colon, Stg III, Chemo +/- Atezol, ATOMIC ALLIANCE 12SEP2017:00:00:00   59   0.5  
    A021602 PANC, Adv PNET Blinded Cabozantinib v Placebo ALLIANCE 18JUL2018:00:00:00   17   0.2  
    A021703 COLON, Adv/Met, Chemo + Std v High dose V-D3 ALLIANCE 30SEP2019:00:00:00   24   0.8  
    A021806 Pancreas, Perioperative vs Adjuvant Chemo ALLIANCE 01JUL2020:00:00:00   16   0.5  
    EA2176 Anal, Met, Immune Check Pt Inhibition + Chemo ECOG-ACRIN 15OCT2020:00:00:00   12   1.2  
    NRGGI004 Colorectal, Stg IV, dMMR Immuno-Therapy NRG 07NOV2017:00:00:00 55 15   0.0  
GU II A031701 Bladder, ddGC for MIBC with DDR Tumor Alt ALLIANCE 01AUG2018:00:00:00   10   0.3  
    A031702 GU, Mets, Cabozantinib+Nivo+Ipi (ICONIC) ALLIANCE 12APR2019:00:00:00   23   0.5  
    A031801 GU, mRCC, Cabozantinib +/- Radium-223 ALLIANCE 13DEC2019:00:00:00   6   0.3  
    A031803 Blad, NMIBC, Gemcitabine + MK-3475 ALLIANCE 06JAN2020:00:00:00   24   1.2  
    EA8171 PROS, newly diagnosed, mpMRI for pre-op stagi ECOG-ACRIN 09JUL2018:00:00:00   70   1.7  
    S2011 Blad, MIBC,Gem+Carbo+Avelumab+Srg vs Srg Only SWOG 06OCT2021:11:28:41 8 0 196 0.0 > 15 Yrs
  II-III EA8192 Blad, High Grade UTUC, Durv + Chemo ECOG-ACRIN 06MAY2021:00:00:00   1   0.2  
    NRGGU002 Pros, RT + ADT After RP +/- Adj Docetaxel NRG 30DEC2016:00:00:00   4   0.0  
  III A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) ALLIANCE 01JUL2015:00:00:00   12   0.2  
    A031704 RCC, Met, Ipi+Nivo followed by Nivo+/-Cabo ALLIANCE 09MAY2019:00:00:00   90   1.8  
    A031902 Pros, Adv, Enzalutamide + Rucaparib ALLIANCE 19FEB2021:00:00:00   4   0.2  
    EA8134 Penile, Local Adv, ILND +/- Chemo or ChemoRT ECOG-ACRIN 08SEP2017:00:00:00   8   0.0  
    EA8183 Pros, Dbl Blind Andro Dep + Daro vs Placebo ECOG-ACRIN 09DEC2020:00:00:00   3   0.0  
    EA8191 Pros, Local vs Systemic Thrpy ECOG-ACRIN 08OCT2020:00:00:00   1   0.0  
    NRGGU005 PROS, intmd risk, IGRT& SBRT vs IGRT& HF-IMRT NRG 16NOV2017:00:00:00   9   0.0  
    NRGGU009 Pros, PREDICT-RT NRG 15DEC2020:00:00:00   3   0.5  
    NRGGU010 Pros, Parallel De-Intens & Intens Trials NRG 03NOV2021:00:00:00   3   0.5  
    S1802 Pros, Stg IV, SST +/- Surg/RT to Primary Tum SWOG 17SEP2018:00:00:00 45 565 1273 11.3 Sep-2027
    S1806 Blad, MIBC, ChemoRT +/- Atezolizumab SWOG 19APR2019:00:00:00 38 294 475 9.7 Jan-2024
    S1931 RENAL, Stg IV, IO + Nephrectomy. vs IO Only SWOG 16NOV2020:00:00:00 19 33 332 2.7 Nov-2031
    S1937 Blad, Mets, Eribulin +/- Gem vs SOC SWOG 16FEB2021:00:00:00 16 10 465 1.0 > 15 Yrs
LEUK I-II S1905 T-ALL/T-LBL, Rel/Ref, OBI-3424 SWOG 17AUG2020:00:00:00 22 10 64 0.3 Dec-2035
  II A041703 ALL, Newly Dx, Inotuzumab Ozogamicin + Blinat ALLIANCE 16NOV2018:00:00:00   4   0.0  
    EA9171 CML, Anti-PD-1 Pembrolizumab + TKIs ECOG-ACRIN 03OCT2018:00:00:00   2   0.0  
    S1712 CML, Chronic Phase, TKI +/- Ruxolitinib SWOG 20JUL2018:00:00:00 47 76 84 1.8 Nov-2022
  II-III A041701 AML, Age 60+, Conv Chemo +/- Uproleselan ALLIANCE 16JAN2019:00:00:00   38   0.0  
  III A041501 B-Cell ALL, Frontline Tx +/- Intuzumab Ozo ALLIANCE 01JUN2017:00:00:00   44   1.0  
    A041702 CLL, Stg I-IV, IO with IM versus IVO ALLIANCE 04JAN2019:00:00:00   64   1.3  
    EA9181 ALL, BCR-ABL+, Steroids+TKI+CT/Blinatumomab ECOG-ACRIN 14OCT2020:00:00:00   16   0.7  
    S1925 CLL/SLL, Newly Dx HR, Early vs Delayed V+O SWOG 14DEC2020:00:00:00 18 27 247 2.2 Dec-2030
LUNG II EA5191 NSCLC, Cabozantinib +/- Nivolumab vs Chemo ECOG-ACRIN 22MAY2020:00:00:00   5   0.5  
    S1701 Thymic Adv, Carbo/Pac/Ram vs. Carbo/Pac SWOG 09AUG2018:00:00:00 46 18 66 0.3 Jun-2034
    S1900E KRAS G12C: Sotorasib (AMG 510) SWOG 02APR2021:00:00:00 15 66 116 3.0 Nov-2023
    S1929 ESCLC, SLFN11+, Atezolizumab ± Talazoparib SWOG 15JUN2020:10:13:46 24 83 94 4.7 Sep-2022
    S1933 NSCLC, Stg II-III, RT + Atezo SWOG 15JUN2020:10:15:53 24 23 47 0.8 Nov-2024
    S1934 Superior Sulcus NSCLC, Trimodality +/- Atezo SWOG 09SEP2021:11:49:38 9 0 74 0.0 > 15 Yrs
  II-III NRGCC003 SCLC, PCI or HA-PCI NRG 07DEC2015:00:00:00   5   0.0  
    NRGLU002 LUNG, Limited Met NSCLC, MST vs LCT + MST NRG 07APR2017:00:00:00   2   0.0  
    NRGLU005 LUNG, LS-SCLC, ChemoRT v ChemoRT+Atezo NRG 28MAY2019:00:00:00   14   0.8  
    S1800D Non-Match: N-803 + Pembro vs SoC SWOG 15FEB2022:00:00:00 4 25 478 5.3 Jul-2029
  III A081801 ALCHEMIST4, ALK and EGFR negative, Chemo-IO ALLIANCE 03JUN2020:00:00:00   36   0.8  
    E4512 ALCHEMIST2, ALK mut, Crizotinib ECOG-ACRIN 18AUG2014:00:00:00   17   0.0  
    EA5163 NSCLC, Immunotherapy +/- 2nd line therapy ECOG-ACRIN 28FEB2019:00:00:00   52   1.2  
    EA5181 NSCLC, Unresect Stg 3, Chemo/RT+/-MED4736 ECOG-ACRIN 09APR2020:00:00:00   40   1.7  
    EA5182 NSCLC, Met EGFR mut, AZD9291+Beva vs AZD9291 ECOG-ACRIN 22OCT2020:00:00:00   3   0.2  
    R1308 Lung, Stg II/III, Photon vs Proton Chemo RT NRG 03FEB2014:00:00:00   1   0.0  
    S1827 SCLC, MRI Surveillance +/- PCI SWOG 10JAN2020:00:00:00 29 102 668 5.3 May-2031
    S1914 NSCLC, High Risk Early Stg, SBRT +/- Atezo SWOG 25MAR2020:00:00:00 27 108 480 5.8 Oct-2027
  OTHER A151216 ALCHEMIST0 - screening ALLIANCE 06FEB2014:00:00:00   916   1.2  
    LUNGMAP NSCLC, Adv, Master SWOG 28JAN2019:00:00:00 41 2567   48.3  
LYMPH I-II E4412 HD, RR, Ipilimumab +Nivo +Brentuximab Vedotin ECOG-ACRIN 24JAN2014:00:00:00   20   0.0  
  II EA4181 MCL, Randomization BR/CR v BR/CR-A v BR-A ECOG-ACRIN 03OCT2019:00:00:00   64   2.2  
    S1608 FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob SWOG 10AUG2017:00:00:00   72 103   Temp Close
  II-III A051701 LYMPH, MYC/BC2 DHL&DEL, R-chemo+/-Venetoclax ALLIANCE 07AUG2019:00:00:00   34     Sep-2020 Temp Close
    S1918 DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP SWOG 19MAR2021:00:00:00 15 35 422 2.7 Aug-2034
  III A051301 ABC DLBCL, Auto HCT and Ibrutinib/Placebo ALLIANCE 06JUL2016:00:00:00   12   0.0  
    ANHL1931 PMBCL, Chemo-Immunotherapy +/- Nivo COG 07JUN2021:00:00:00   1   0.2  
    EA4151 Lymph, AHCT +/-Ritux, MRD Neg ECOG-ACRIN 29AUG2017:00:00:00   103   2.8  
    S1826 HD, Adv, Age 12+, N+AVD vs BV+AVD SWOG 19JUL2019:00:00:00 35 894 987 36.8 Sep-2022
MELAN II EA6192 Melan, Adv, Erly Discont of Antibdy Thrpy ECOG-ACRIN 27AUG2020:00:00:00   3   0.2  
    S2000 MELAN, M1d/ BRAF, Enco+Bini+Nivo vs Ipil+Nivo SWOG 23SEP2020:00:00:00 21 12 112 0.3 > 15 Yrs
  II-III EA6141 Melan, Adv, Nivolumab+Ipi ± Sargmostim ECOG-ACRIN 01MAR2016:00:00:00   46   0.7  
  III EA6174 Merkel, Adjuvant Pembrolizumab vs Observation ECOG-ACRIN 23JUL2018:00:00:00   42   1.0  
MMYEL II EAA173 MYEL, SMM, Rd +/- Daratumumab ECOG-ACRIN 30APR2019:00:00:00   19   0.5  
    S2005 WM, Prev. Untreated, I/R +/- Venetoclax SWOG 24JUN2021:00:00:00 12 1 62 0.2 > 15 Yrs
  III EAA181 Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) ECOG-ACRIN 27OCT2020:00:00:00   7   0.7  
    S1803 MM, Maintenance, Len vs Len/Dara SWOG 27JUN2019:00:00:00 36 801 1100 26.2 Jun-2023
OTHER II A071701 BRAIN, Met, Geno-guided trial ALLIANCE 15AUG2019:00:00:00   1   0.0  
    A091802 cSCC, Advanced Avelumab +/- Cetuximab ALLIANCE 17MAY2019:00:00:00   5   0.0  
    A091902 Sarcoma, Paclit +/- Nivo and Nivo + Caboz ALLIANCE 04SEP2020:00:00:00   18   0.7  
    EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp ECOG-ACRIN 29MAR2016:00:00:00   20   0.0  
    EA3163 Nasal, T3 vs T4a, Surgery+RT +/- NeoAdj CT ECOG-ACRIN 28MAR2018:00:00:00   1   0.0  
    EA3191 HN, High Risk HNSCC, Adj +/- Pembro ECOG-ACRIN 08JAN2021:00:00:00   2   0.3  
    EAF151 Brain, GBM, Bev, Blood Volume ECOG-ACRIN 14APR2017:00:00:00   2   0.0  
    NRGBN001 HN, novel vs. std chemoradiation + chemo NRG 28AUG2015:00:00:00   1   0.0  
    NRGGY023 Ovar, Rando Durv Triplet TX vs Chemo NRG 28APR2021:00:00:00   2   0.2  
  II-III EA3161 HNC, HPV+ OPCA, (cisplatin+RT) +/- Nivo ECOG-ACRIN 20JUN2019:00:00:00   38   2.0  
    NRGBN007 Brain, New Dx, Ipi + Nivo vs Temozomide NRG 06AUG2020:00:00:00   5   0.2  
    NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care NRG 06FEB2016:00:00:00   4   0.0  
    NRGHN001 Nasopharyngeal , Indiviual Tx EBV NRG 21APR2014:00:00:00   7   0.0  
    NRGHN004 HN, Adv, RT+Durvalumab vs RT+Cetuximab NRG 12DEC2017:00:00:00   6   0.0  
    NRGHN005 HN, early stg P16-pos, randomize de-intensifi NRG 10JUL2019:00:00:00   6   0.0  
    NRGHN006 HN, Erly Stg, Biopsy vs Dissection NRG 08JUL2020:00:00:00   1   0.0  
    NRGHN009 HN, RT + HD Cisp vs RT + LD Cisp for SCCHN NRG 27OCT2021:00:00:00   2   0.3  
    R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux NRG 18MAR2013:00:00:00   5   0.0  
  III A071801 Brain, Mets, Post-Srg Single SRS vs Fract SRS ALLIANCE 11OCT2019:00:00:00   1   0.0  
    AGCT1532 Inter/Poor Met GCTs, Accel v Std BEP Chemo COG 30JUL2018:00:00:00   4     Jan-2021 Temp Close
    ARST1431 Sarcoma, IR RMS, Randomized VAC/VI +/- TORI COG 23MAY2016:00:00:00   1   0.0  
    G0263 Cerv, Stg I/IIA, adjv RT vs chemoRT NRG 12APR2010:00:00:00   1   0.0  
    N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC ALLIANCE 22SEP2009:00:00:00   13   0.2  
    NRGBN003 Mening, Grd II, Observation vs Irradiation NRG 14JUN2017:00:00:00   3   0.0  
    NRGGY018 Endo, Stg III-IVB/Recur, Pac/Carbo +/- Pembro NRG 16JUL2019:00:00:00   4   0.2  
    NRGGY020 Endo, Erly Stg, Rando RT +/- Pembro NRG 07FEB2020:00:00:00   1   0.0  
    R0724 Cervical, Chem+RT +/- Adj. Chemo NRG 15JAN2014:00:00:00   1   0.0  
  OTHER A151804 irAEs, National Biorepository to Adv Studies ALLIANCE 31JAN2020:00:00:00   16   0.0  
    NCICOVID NCI COVID-19 in Cancer Patients Study NCI 21MAY2020:00:00:00   329   7.2  
PREV II EA2185 Panc, Impact of Panc Cyst Surveillance ECOG-ACRIN 16JAN2020:00:00:00   8   0.5  
  III A211102 Breast, Atypia via RPFNA, Metformin v Placebo ALLIANCE 01FEB2015:00:00:00   3   0.0  
    EA1151 Prev, Tomosynthesis Mammographic Screening ECOG-ACRIN 06JUL2017:00:00:00   2133   39.5  
    S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac SWOG 01MAR2013:00:00:00 112 339 491 2.2 May-2028
  OTHER NRGCC008 Ovar, BRCA1, non-inferiority of BLS vs BSO NRG 23JUN2020:00:00:00   2   0.2  
    S1823 GCT, Obs. Cohort, miRNA371 SWOG 01JUN2020:13:00:37 25 528 956 22.8 Jan-2024
  PILOT S1904 Breast, Decision making for chemoprevention SWOG 01SEP2020:00:00:00 22 183 415 12.7 Jan-2024
SURV III S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol SWOG 15SEP2017:00:00:00 57 273 817 2.2 > 15 Yrs
SXQOL II EAZ171 Breast, Stg I-III, TIPN Docetaxel/Paclitaxel ECOG-ACRIN 27JUN2019:00:00:00   3   0.0  
  II-III A221805 Colorectal, Duloxetine for Oxaliplatin CIPN ALLIANCE 01MAY2020:00:00:00   5   0.2  
  III A221702 BREAST, SLN/ALND +/- ARM ALLIANCE 31MAY2019:00:00:00   17   0.3  
    A222004 Mult, Olanza vs Megestrol for Anorexia ALLIANCE 15OCT2021:00:00:00   2   0.3  
    S1600 Bladder,Radical Cystectomy Outcomes Nutrition SWOG 21FEB2019:00:00:00 40 140 200 3.0 Feb-2024
    S1614 HBV in Ca Pts, anti-HBV therapy vs SOC SWOG 21FEB2019:00:00:00 40 4 444 0.2 > 15 Yrs
  OTHER S2013 I-CHECKIT: ICI toxicity risk prediction study SWOG 16AUG2021:00:00:00 10 309 2062 41.7 Jan-2026
  PILOT EAQ202 Improving AYA PROs in EA Trials ECOG-ACRIN 28OCT2021:00:00:00   32   4.3  
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.

05-JUL-2022 6:11

OPEN AND TEMPORARILY CLOSED STUDIES: BY STUDY TYPE, COMMITTEE, INTERGROUP, SWOG/OTHER STAT CENTER

Phase Comm. Int
grp		 Stat
Center		 Study NCIPROTO CA
Cntrl
Study		 Temp
Close
BIOL   N   SLA01 LA Gastric Ca, Immune Checkpoint Expression   N  
OTHER CCD Y COG ACCL16N1 Guideline Consistent Treatment AYA ALL ACCL16N1CD Y Y
    Y ECOG-ACRIN NHLBIMDS LEUK, National MDS Study NHLBI-MDS Y  
    Y ALLIANCE A231602C Blood Cancer, Assess Financial Difficulty A231602CD Y Y
    Y NRG NRGCC007 CCD, Increased Dose of SCP in Pros Survivors NRG-CC007CD Y  
    Y ALLIANCE A231701C Brst, Srg Decision Engagement A231701CD Y  
    Y ALLIANCE A231601C CCD, OPTI-Surg in older cancer patients A231601CD Y  
    Y ALLIANCE A231901C Breast, Shared Decision Engagement System A231901CD Y  
  ERLYTX Y ECOG-ACRIN EAY131 MATCH EAY131 N  
  LUNG Y SWOG LUNGMAP NSCLC, Adv, Master LUNGMAP N  
    Y ALLIANCE A151216 ALCHEMIST0 - screening A151216 N  
  OTHER Y ALLIANCE A151804 irAEs, National Biorepository to Adv Studies A151804 N  
    Y NCI NCICOVID NCI COVID-19 in Cancer Patients Study NCICOVID N  
  PREV Y SWOG S1823 GCT, Obs. Cohort, miRNA371 S1823 Y  
    Y NRG NRGCC008 Ovar, BRCA1, non-inferiority of BLS vs BSO NRG-CC008 Y  
  SXQOL Y SWOG S2013 I-CHECKIT: ICI toxicity risk prediction study S2013 Y  
I-II BREAST Y ECOG-ACRIN EA1183 Brst, Met, FDG PET Assess Response, FEATURE EA1183 N  
  LEUK Y SWOG S1905 T-ALL/T-LBL, Rel/Ref, OBI-3424 S1905 N  
  LYMPH Y ECOG-ACRIN E4412 HD, RR, Ipilimumab +Nivo +Brentuximab Vedotin E4412 N  
II BREAST Y SWOG S1706 Breast, Inflammatory, RT +/- Olaparib S1706 Y  
    Y SWOG S2007 Breast, Brain Mets, Sacituzumab Govitecan S2007 N  
    Y NRG NRGBR005 Br, Stg II&IIIA, Post NAdj Chemo Br Conserv NRG-BR005 N Y
    Y ECOG-ACRIN EA1181 BRST, HER2-pCR, Preop THP and Postop HP EA1181 N  
  CCD Y ECOG-ACRIN EAQ171CD Smoke Free Support Study 2.0 EAQ171CD Y  
  ERLYTX Y SWOG S1609 Rare Tumor, Comb Nivo/Ipi S1609 N  
  GI Y SWOG S2001 Rando II, Mets Pancreas , BRCA1/2, Comb Chemo S2001 N  
    Y SWOG S1922 Small Bowel,Ram+Pac vs FOLFIRI, mets/unresect S1922 N  
    Y SWOG S2107 Colorectal, BRAF mut, Enc + CET +/-Nivo S2107 N  
    Y SWOG S2104 Panc,Resect High-risk,Postop Adj Chemo vs Obs S2104 N  
    Y ECOG-ACRIN EA2186 PANC, mets, Gem+Abraxane vs 5-FU+LV+Nal-IRI EA2186 Y  
    Y ECOG-ACRIN EA2182 Anal, Erly, DECREASE EA2182 Y  
    Y ECOG-ACRIN EA2187 ICC, Carboplatin+Paclitaxel +/- Pevonedistat EA2187 N  
  GU Y SWOG S2011 Blad, MIBC,Gem+Carbo+Avelumab+Srg vs Srg Only S2011 N  
    Y ECOG-ACRIN EA8171 PROS, newly diagnosed, mpMRI for pre-op stagi EA8171 N  
    Y ALLIANCE A031701 Bladder, ddGC for MIBC with DDR Tumor Alt A031701 N  
    Y ALLIANCE A031702 GU, Mets, Cabozantinib+Nivo+Ipi (ICONIC) A031702 N  
    Y ALLIANCE A031803 Blad, NMIBC, Gemcitabine + MK-3475 A031803 N  
    Y ALLIANCE A031801 GU, mRCC, Cabozantinib +/- Radium-223 A031801 Y  
  LEUK Y SWOG S1712 CML, Chronic Phase, TKI +/- Ruxolitinib S1712 N  
    Y ECOG-ACRIN EA9171 CML, Anti-PD-1 Pembrolizumab + TKIs EA9171 N  
    Y ALLIANCE A041703 ALL, Newly Dx, Inotuzumab Ozogamicin + Blinat A041703 N  
  LUNG Y SWOG S1929 ESCLC, SLFN11+, Atezolizumab ± Talazoparib S1929 N  
    Y SWOG S1933 NSCLC, Stg II-III, RT + Atezo S1933 N  
    Y SWOG S1701 Thymic Adv, Carbo/Pac/Ram vs. Carbo/Pac S1701 N  
    Y SWOG S1900E KRAS G12C: Sotorasib (AMG 510) S1900E N  
    Y SWOG S1934 Superior Sulcus NSCLC, Trimodality +/- Atezo S1934 N  
    Y ECOG-ACRIN EA5191 NSCLC, Cabozantinib +/- Nivolumab vs Chemo EA5191 N  
  LYMPH Y SWOG S1608 FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob S1608 N Y
    Y ECOG-ACRIN EA4181 MCL, Randomization BR/CR v BR/CR-A v BR-A EA4181 N  
  MELAN Y SWOG S2000 MELAN, M1d/ BRAF, Enco+Bini+Nivo vs Ipil+Nivo S2000 N  
    Y ECOG-ACRIN EA6192 Melan, Adv, Erly Discont of Antibdy Thrpy EA6192 N  
  MMYEL Y SWOG S2005 WM, Prev. Untreated, I/R +/- Venetoclax S2005 N  
    Y ECOG-ACRIN EAA173 MYEL, SMM, Rd +/- Daratumumab EAA173 Y  
  OTHER Y NRG NRGBN001 HN, novel vs. std chemoradiation + chemo NRG-BN001 N  
    Y ECOG-ACRIN EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp EA3132 N  
    Y ECOG-ACRIN EAF151 Brain, GBM, Bev, Blood Volume EAF151 N  
    Y ECOG-ACRIN EA3163 Nasal, T3 vs T4a, Surgery+RT +/- NeoAdj CT EA3163 N  
    Y ALLIANCE A091802 cSCC, Advanced Avelumab +/- Cetuximab A091802 N  
    Y ALLIANCE A071701 BRAIN, Met, Geno-guided trial A071701 N  
    Y ALLIANCE A091902 Sarcoma, Paclit +/- Nivo and Nivo + Caboz A091902 N  
    Y ECOG-ACRIN EA3191 HN, High Risk HNSCC, Adj +/- Pembro EA3191 N  
    Y NRG NRGGY023 Ovar, Rando Durv Triplet TX vs Chemo NRG-GY023 N  
  PREV Y ECOG-ACRIN EA2185 Panc, Impact of Panc Cyst Surveillance EA2185 Y  
  SXQOL Y ECOG-ACRIN EAZ171 Breast, Stg I-III, TIPN Docetaxel/Paclitaxel EAZ171 Y  
PILOT PREV Y SWOG S1904 Breast, Decision making for chemoprevention S1904 Y  
  SXQOL Y ECOG-ACRIN EAQ202 Improving AYA PROs in EA Trials EAQ202 Y  
II-III BREAST Y NRG NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA NRG-BR002 N Y
  ERLYTX Y SWOG S2012 Small Cell NEC, Stg IV, Combo Chemo +/- Atezo S2012 N  
  GI Y NRG NRGGI005 COLON,Stg IIA, ctDNA in Adjuvant Chemotherapy NRG-GI005 N  
    Y ECOG-ACRIN EA2197 Gal, Rando Perioperative TX EA2197 N  
    Y ECOG-ACRIN EA2174 Esoph, Peri-Op Nivolumab +/- Ipilimumab EA2174 N  
  GU Y NRG NRGGU002 Pros, RT + ADT After RP +/- Adj Docetaxel NRG-GU002 N  
    Y ECOG-ACRIN EA8192 Blad, High Grade UTUC, Durv + Chemo EA8192 N  
  LEUK Y ALLIANCE A041701 AML, Age 60+, Conv Chemo +/- Uproleselan A041701 N  
  LUNG Y SWOG S1800D Non-Match: N-803 + Pembro vs SoC S1800D N  
    Y NRG NRGCC003 SCLC, PCI or HA-PCI NRG-CC003 Y  
    Y NRG NRGLU005 LUNG, LS-SCLC, ChemoRT v ChemoRT+Atezo NRG-LU005 Y  
    Y NRG NRGLU002 LUNG, Limited Met NSCLC, MST vs LCT + MST NRG-LU002 Y  
  LYMPH Y SWOG S1918 DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP S1918 Y  
    Y ALLIANCE A051701 LYMPH, MYC/BC2 DHL&DEL, R-chemo+/-Venetoclax A051701 N Y
  MELAN Y ECOG-ACRIN EA6141 Melan, Adv, Nivolumab+Ipi ± Sargmostim EA6141 N  
  OTHER Y NRG NRGHN004 HN, Adv, RT+Durvalumab vs RT+Cetuximab NRG-HN004 Y  
    Y NRG NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care NRG-GY005 Y  
    Y NRG NRGHN005 HN, early stg P16-pos, randomize de-intensifi NRG-HN005 Y  
    Y ECOG-ACRIN EA3161 HNC, HPV+ OPCA, (cisplatin+RT) +/- Nivo EA3161 N  
    Y NRG R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux RTOG-1216 Y  
    Y NRG NRGHN001 Nasopharyngeal , Indiviual Tx EBV NRG-HN001 Y  
    Y NRG NRGHN006 HN, Erly Stg, Biopsy vs Dissection NRG-HN006 Y  
    Y NRG NRGHN009 HN, RT + HD Cisp vs RT + LD Cisp for SCCHN NRG-HN009 Y  
    Y NRG NRGBN007 Brain, New Dx, Ipi + Nivo vs Temozomide NRG-BN007 Y  
  SXQOL Y ALLIANCE A221805 Colorectal, Duloxetine for Oxaliplatin CIPN A221805 Y  
III BREAST Y ALLIANCE A011202 Breast, Nodal XRT +/- ALND A011202 N  
    Y NRG NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo NRG-BR003 N  
    Y NRG NRGBR004 BREAST, Met HER2+, Pac+Tras+Pert +/- Atezo NRG-BR004 Y  
    Y CCTG MA39 BREAST, Node-Pos, Reg RT vs No Reg RT CCTG MA.39 Y  
    Y ALLIANCE A011801 BRST, HER2+, T-DM1+Placebo v T-DM1+Tucatinib A011801 Y  
    Y NRG NRGBR007 Breast, Stg I, De-Escalation of Breast RT NRG-BR007 Y  
  CCD Y SWOG S1703 Met Breast, STM-monitoring v Usual Care S1703 Y  
    Y SWOG S1912CD CREDIT, Fin Counseling to reduce Fin Hardship S1912CD Y  
    Y ALLIANCE A191901 Brst, Text/Motivational Intervention ET Adher A191901 Y  
  ERLYTX Y COG AGCT1531 Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult AGCT1531 Y  
  GI Y ALLIANCE A021502 Colon, Stg III, Chemo +/- Atezol, ATOMIC A021502 Y  
    Y NRG NRGGI004 Colorectal, Stg IV, dMMR Immuno-Therapy NRG-GI004 Y  
    Y ALLIANCE A021602 PANC, Adv PNET Blinded Cabozantinib v Placebo A021602 Y  
    Y ALLIANCE A021703 COLON, Adv/Met, Chemo + Std v High dose V-D3 A021703 N  
    Y ALLIANCE A021806 Pancreas, Perioperative vs Adjuvant Chemo A021806 Y  
    Y ECOG-ACRIN EA2176 Anal, Met, Immune Check Pt Inhibition + Chemo EA2176 N  
  GU Y SWOG S1806 Blad, MIBC, ChemoRT +/- Atezolizumab S1806 Y  
    Y SWOG S1802 Pros, Stg IV, SST +/- Surg/RT to Primary Tum S1802 Y  
    Y SWOG S1937 Blad, Mets, Eribulin +/- Gem vs SOC S1937 N  
    Y SWOG S1931 RENAL, Stg IV, IO + Nephrectomy. vs IO Only S1931 N  
    Y NRG NRGGU005 PROS, intmd risk, IGRT& SBRT vs IGRT& HF-IMRT NRG-GU005 Y  
    Y ALLIANCE A031704 RCC, Met, Ipi+Nivo followed by Nivo+/-Cabo A031704 Y  
    Y ECOG-ACRIN EA8134 Penile, Local Adv, ILND +/- Chemo or ChemoRT EA8134 Y  
    Y ALLIANCE A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) A031102 Y  
    Y NRG NRGGU010 Pros, Parallel De-Intens & Intens Trials NRG-GU010 Y  
    Y ECOG-ACRIN EA8191 Pros, Local vs Systemic Thrpy EA8191 N  
    Y ECOG-ACRIN EA8183 Pros, Dbl Blind Andro Dep + Daro vs Placebo EA8183 Y  
    Y NRG NRGGU009 Pros, PREDICT-RT NRG-GU009 Y  
    Y ALLIANCE A031902 Pros, Adv, Enzalutamide + Rucaparib A031902 Y  
  LEUK Y SWOG S1925 CLL/SLL, Newly Dx HR, Early vs Delayed V+O S1925 Y  
    Y ALLIANCE A041702 CLL, Stg I-IV, IO with IM versus IVO A041702 N  
    Y ALLIANCE A041501 B-Cell ALL, Frontline Tx +/- Intuzumab Ozo A041501 N  
    Y ECOG-ACRIN EA9181 ALL, BCR-ABL+, Steroids+TKI+CT/Blinatumomab EA9181 N  
  LUNG Y SWOG S1827 SCLC, MRI Surveillance +/- PCI S1827 Y  
    Y SWOG S1914 NSCLC, High Risk Early Stg, SBRT +/- Atezo S1914 Y  
    Y ECOG-ACRIN EA5181 NSCLC, Unresect Stg 3, Chemo/RT+/-MED4736 EA5181 N  
    Y ECOG-ACRIN E4512 ALCHEMIST2, ALK mut, Crizotinib E4512 N  
    Y ECOG-ACRIN EA5163 NSCLC, Immunotherapy +/- 2nd line therapy EA5163 N  
    Y ALLIANCE A081801 ALCHEMIST4, ALK and EGFR negative, Chemo-IO A081801 Y  
    Y ECOG-ACRIN EA5182 NSCLC, Met EGFR mut, AZD9291+Beva vs AZD9291 EA5182 N  
    Y NRG R1308 Lung, Stg II/III, Photon vs Proton Chemo RT RTOG-1308 Y  
  LYMPH Y SWOG S1826 HD, Adv, Age 12+, N+AVD vs BV+AVD S1826 Y  
    Y ALLIANCE A051301 ABC DLBCL, Auto HCT and Ibrutinib/Placebo A051301 N  
    Y ECOG-ACRIN EA4151 Lymph, AHCT +/-Ritux, MRD Neg EA4151 N  
    Y COG ANHL1931 PMBCL, Chemo-Immunotherapy +/- Nivo ANHL1931 N  
  MELAN Y ECOG-ACRIN EA6174 Merkel, Adjuvant Pembrolizumab vs Observation EA6174 N  
  MMYEL Y SWOG S1803 MM, Maintenance, Len vs Len/Dara S1803 N  
    Y ECOG-ACRIN EAA181 Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) EAA181 Y  
  OTHER Y ALLIANCE N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC N0577 N  
    Y NRG G0263 Cerv, Stg I/IIA, adjv RT vs chemoRT GOG-0263 Y  
    Y NRG NRGBN003 Mening, Grd II, Observation vs Irradiation NRG-BN003 Y  
    Y COG AGCT1532 Inter/Poor Met GCTs, Accel v Std BEP Chemo AGCT1532 Y Y
    Y NRG R0724 Cervical, Chem+RT +/- Adj. Chemo RTOG-0724 Y  
    Y ALLIANCE A071801 Brain, Mets, Post-Srg Single SRS vs Fract SRS A071801 Y  
    Y NRG NRGGY018 Endo, Stg III-IVB/Recur, Pac/Carbo +/- Pembro NRG-GY018 Y  
    Y COG ARST1431 Sarcoma, IR RMS, Randomized VAC/VI +/- TORI ARST1431 N  
    Y NRG NRGGY020 Endo, Erly Stg, Rando RT +/- Pembro NRG-GY020 Y  
  PREV Y SWOG S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac S0820 Y  
    Y ECOG-ACRIN EA1151 Prev, Tomosynthesis Mammographic Screening EA1151 N  
    Y ALLIANCE A211102 Breast, Atypia via RPFNA, Metformin v Placebo A211102 Y  
  SURV Y SWOG S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol S1501 Y  
  SXQOL Y SWOG S1600 Bladder,Radical Cystectomy Outcomes Nutrition S1600 Y  
    Y SWOG S1614 HBV in Ca Pts, anti-HBV therapy vs SOC S1614 Y  
    Y ALLIANCE A221702 BREAST, SLN/ALND +/- ARM A221702 Y  
    Y ALLIANCE A222004 Mult, Olanza vs Megestrol for Anorexia A222004 Y  
    Y SWOG S2015 S2015    

05-JUL-2022 6:11

PHASE III SWOG COORDINATED OPEN STUDIES

SORTED BY STUDY ID

Protocol
Number		 Study Accrual
Goal		 Open
Stat/Date		 Months
Open		 Accrual
as of
01Jan02		 Current Accrual Proj.
Annual
Accr.
Rate		 EXPCLOSE Proj.
Study
Duration
(Years)
S0820 S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac (PREV) 491 Y-03/01/13 112 339 339 26 May-2028 > 15 Yrs
S1501 S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol (SURV) 817 Y-09/15/17 57 273 273 26 > 15 Yrs > 15 Yrs
S1600 S1600 Bladder,Radical Cystectomy Outcomes Nutrition (SXQOL) 200 Y-02/21/19 40 140 140 36 Feb-2024 5.0
S1614 S1614 HBV in Ca Pts, anti-HBV therapy vs SOC (SXQOL) 444 Y-02/21/19 40 4 4 2 > 15 Yrs > 15 Yrs
S1703 S1703 Met Breast, STM-monitoring v Usual Care (CCD) 1320 Y-07/16/18 47 228 228 56 > 15 Yrs > 15 Yrs
S1800D S1800D Non-Match: N-803 + Pembro vs SoC (LUNG) 478 Y-02/15/22 4 25 25 64.024115 Jul-2029 7.4
S1802 S1802 Pros, Stg IV, SST +/- Surg/RT to Primary Tum (GU) 1273 Y-09/17/18 45 565 565 136 Sep-2027 9.0
S1803 S1803 MM, Maintenance, Len vs Len/Dara (MMYEL) 1100 Y-06/27/19 36 801 801 314 Jun-2023 3.9
S1806 S1806 Blad, MIBC, ChemoRT +/- Atezolizumab (GU) 475 Y-04/19/19 38 294 294 116 Jan-2024 4.7
S1826 S1826 HD, Adv, Age 12+, N+AVD vs BV+AVD (LYMPH) 987 Y-07/19/19 35 894 894 442 Sep-2022 3.1
S1827 S1827 SCLC, MRI Surveillance +/- PCI (LUNG) 668 Y-01/10/20 29 102 102 64 May-2031 11.3
S1912CD S1912CD CREDIT, Fin Counseling to reduce Fin Hardship (CCD) 536 Y-07/26/21 11 30 30 48 Jan-2033 11.4
S1914 S1914 NSCLC, High Risk Early Stg, SBRT +/- Atezo (LUNG) 480 Y-03/25/20 27 108 108 70 Oct-2027 7.5
S1918 S1918 DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP (LYMPH) 422 Y-03/19/21 15 35 35 32 Aug-2034 13.4
S1925 S1925 CLL/SLL, Newly Dx HR, Early vs Delayed V+O (LEUK) 247 Y-12/14/20 18 27 27 26 Dec-2030 10.0
S1931 S1931 RENAL, Stg IV, IO + Nephrectomy. vs IO Only (GU) 332 Y-11/16/20 19 33 33 32 Nov-2031 11.0
S1937 S1937 Blad, Mets, Eribulin +/- Gem vs SOC (GU) 465 Y-02/16/21 16 10 10 12 > 15 Yrs > 15 Yrs
S2012 S2012 Small Cell NEC, Stg IV, Combo Chemo +/- Atezo (ERLYTX) 189 Y-12/02/21 7 1 1 2 > 15 Yrs > 15 Yrs
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.